

0020-4843P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/807459
NEW

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP99/04386	August 13, 1999	-----

TITLE OF INVENTION

GENE ENCODING PROTEIN FROM MERZOITE OF BABESIA CABALLI, RECOMBINANT PROTEIN OBTAINED WITH *

APPLICANT(S) FOR DO/EO/US

IKADAI, Hiromi; IGARASHI, Ikuo; SUZUKI, Naoyoshi; NAGASAWA, Hideyuki; MAKAMI, Takeshi; **

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau. WO 01/12813 A1
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4)
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 20. below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98./International Search Report
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A FIRST preliminary amendment.
14. A SECOND or SUBSEQUENT preliminary amendment.
15. A substitute specification.
16. A change of power of attorney and/or address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information:

- 1.) Three (3) sheets of Formal Drawings
- 2.) Sequence Listing (5 Pages)

* SAID GENE AND USE THEREOF

**FUJISAKA, Kozo

U.S. APPLICATION NO (if known, see 37 CFR 1.5) 09/807459	INTERNATIONAL APPLICATION NO PCT/JP99/04386	ATTORNEY'S DOCKET NUMBER 0020-4843P																
21. <input checked="" type="checkbox"/> The following fees are submitted. BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1,000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). \$100.00		CALCULATIONS PTO USE ONLY																
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 860.00																
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00																
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">CLAIMS</th> <th style="width: 25%;">NUMBER FILED</th> <th style="width: 25%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>16 - 20 =</td> <td>0</td> <td>X \$18.00</td> </tr> <tr> <td>Independent Claims</td> <td>5 - 3 =</td> <td>2</td> <td>X \$80.00</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>yes</td> <td>+ \$270.00</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total Claims	16 - 20 =	0	X \$18.00	Independent Claims	5 - 3 =	2	X \$80.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)		yes	+ \$270.00	TOTAL OF ABOVE CALCULATIONS = \$ 1420.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE															
Total Claims	16 - 20 =	0	X \$18.00															
Independent Claims	5 - 3 =	2	X \$80.00															
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		yes	+ \$270.00															
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$ 0																
SUBTOTAL =		\$ 1420.00																
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +		\$ 0																
TOTAL NATIONAL FEE =		\$ 1420.00																
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$ 0																
TOTAL FEES ENCLOSED =		\$ 1420.00																
Amount to be: refunded \$ charged \$																		
a. <input checked="" type="checkbox"/> A check in the amount of \$ 1420.00 to cover the above fees is enclosed.																		
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.																		
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2448 .																		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																		
Send all correspondence to: Birch, Stewart, Kolasch & Birch, LLP or Customer No. 2292 P.O. Box 747 Falls Church, VA 22040-0747 (703)205-8000																		
Date: April 13, 2001		By <i>Andrew D. Meikle #32,868</i> Andrew D. Meikle, #32,868																
<i>/ja</i>																		



Rec'd PCT/PTO 14 JUN 2001
09/807459

BOX SEQUENCE
PATENT
0020-4843P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT(S): Hiromi IKADAI et al. Conf. No.:7623

APPLICATION NO.: 09/807,459 GROUP: 5002

FILED: April 13, 2001 EXAMINER: P. Lawrence

FOR: GENE ENCODING PROTEIN FROM MEROZOITE OF BABESIA
CABALLI, RECOMBINANT PROTEIN OBTAINED WITH SAID GENE
AND USE THEREOF

PRELIMINARY AMENDMENT

Honorable Commissioner of Patents
Washington, D.C. 20231

June 14, 2001

Sir:

The following Preliminary Amendment and Remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION

Please amend the specification as follows:

Please delete the Sequence Listing filed April 13, 2001 located immediately after the abstract.

Please insert the Substitute Sequence Listing enclosed herewith in its place.